The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapy
- 397 Downloads
To develop a patient-reported outcome instrument for measuring anemia symptoms and their impact in patients with chemotherapy-induced anemia (CIA).
Qualitative research was conducted using six focus groups and 24 interviews with 46 CIA patients, eight interviews in patients receiving chemotherapy with no CIA history and two interviews in patients successfully treated for CIA. Atlas.ti 5.0 was used to organize key concepts. Cognitive interviews with 16 CIA patients and assessment of relevance of each item to CIA by 10 clinicians were also conducted to evaluate content validity.
Most CIA patients were white (76%) and female (83%), and the average age was 60 years. The most common cancer types were breast cancer (54%) and lung cancer (17%). Tiredness was the most prevalent symptom and rated as the most important by 83% of CIA patients; weakness, shortness of breath, lightheadedness, and dizziness were ranked next in importance. The final anemia impact measure (AIM) contains: (1) daily CIA symptom diary (9 items), and (2) impact of CIA-related tiredness (29 items covering daily living activities, social activities, cognitive function, and emotions). Cognitive interviews found that the AIM was relevant and easy to understand.
The AIM assesses important patient-perceived CIA symptoms and their impact and was developed using extensive patient qualitative data.
KeywordsChemotherapy Anemia Symptom Instrument development Content validity Qualitative research
Activities of Daily Living
Anemia Impact Measure
Electronic Personal Digital Assistant
Functional Assessment of Cancer Therapy-Anemia
Functional Assessment of Cancer Therapy-Fatigue
Food and Drug Administration
Health-Related Quality of Life
Instrumental Activities of Daily Life
Mental Component Summary Score
National Institutes of Health
Physical Component Summary Score
Personal Digital Assistant
The authors thank Mona Martin, RN, MPA, and the research group at Health Research Associates, Inc. for an independent analysis of the data and comments on an earlier draft. The authors thank both Joel Kallich at Amgen Inc. for reviews of the protocol and manuscript and Linda Runft at Amgen Inc. for editorial assistance on the manuscript. The authors also wish to extend their acknowledgment to David Henry, MD; Heinz Ludwig, MD; Barbara Piper, DNSc, RN, AOCN, FAAN, and Lee Schwartzberg, MD, who served as members of the expert panel for their extensive input during the conceptualization and implementation of the instrument development study. Panel members participated in meetings with the authors during protocol development and during the study to discuss the recording and graduation of anemia symptoms and the difficulties in discriminating anemia symptoms from symptoms due to cancer and cancer therapy.
- 2.Knight, K., Wade, S. & Balducci, L. (2004). Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am J Med, 116(Suppl 7A), 11S–26S.Google Scholar
- 3.Merli, F., Bertini, M., Luminari, S., Mozzana, R., Berte, R., Trottini, M., et al. (2004). Quality of life assessment in elderly patients with aggressive non-Hodgkin’s Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi. Haematologica, 89(8), 973–978.PubMedGoogle Scholar
- 4.Pujade-Lauraine, E. & Gascon, P. (2004). The burden of anaemia in patients with cancer. Oncology, 67(Suppl 1), 1–4.Google Scholar
- 5.Bokemeyer, C. & Foubert, J. (2004). Anemia impact and management: focus on patient needs and the use of erythropoietic agents. Semin Oncol, 31(3 Suppl 8), 4–11.Google Scholar
- 8.Kallich, J. D., Tchekmedyian, N. S., Damiano, A. M., Shi, J., Black, J. T. & Erder, M. H. (2002). Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology (Williston Park), 16(9 Suppl 10), 117–124.Google Scholar
- 9.Littlewood, T. J., Kallich, J. D., San Miguel, J., Hendricks, L., & Hedenus, M. (2006). Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies. Journal of Pain and Symptom Management, 31(4), 317–325.PubMedCrossRefGoogle Scholar
- 13.Seidenfeld, J., Piper, M., Bohlius, J., Weingart, O., Trelle, S., Engert, A., et al. (2006). Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. Comparative effectiveness review no. 3. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-02-0026). Available at: http://www.effectivehealthcare.ahrq.gov/reports/final.cfm.
- 14.Bamias, A., Aravantinos, G., Kalofonos, C., Timotheadou, N., Siafaka, V., Vlahou, I., et al. (2003). Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): A prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology, 64(2), 102–110.PubMedCrossRefGoogle Scholar
- 16.Littlewood, T. J., Bajetta, E., Nortier, J. W., Vercammen, E., & Rapoport, B. (2001). Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19(11), 2865–2874.PubMedGoogle Scholar
- 17.de Castro, J., Ordonez, A., Isla, D., Sanchez, A., Arrivi, A., Manzano, J. L., et al. (2007). Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: Results of the NeoPrevent study. Cancer Chemotherapy and Pharmacology, 59(1), 35–42.PubMedCrossRefGoogle Scholar
- 18.Gabrilove, J. L., Cleeland, C. S., Livingston, R. B., Sarokhan, B., Winer, E., & Einhorn, L. H. (2001). Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. Journal of Clinical Oncology, 19(11), 2875–2882.PubMedGoogle Scholar
- 19.Glaspy, J., Vadhan-Raj, S., Patel, R., Bosserman, L., Hu, E., Lloyd, R. E., et al. (2006). Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. Journal of Clinical Oncology, 24(15), 2290–2297.PubMedCrossRefGoogle Scholar
- 20.Cella, D. (1997). The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol, 34(3 Suppl 2), 13–19.Google Scholar
- 24.Witzig, T. E., Silberstein, P. T., Loprinzi, C. L., Sloan, J. A., Novotny, P. J., Mailliard, J. A., et al. (2005). Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. Journal of Clinical Oncology, 23(12), 2606–2617.PubMedCrossRefGoogle Scholar
- 25.Food and Drug Administration (FDA). (2009). Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims. Federal Register, 74(235), 65132–65133.Google Scholar
- 27.Patrick, D. L., Burke, L. B., Powers, J. H., Scott, J. A., Rock, E. P., Dawisha, S., et al. (2007). Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health, 10(Suppl 2), S125–137.Google Scholar
- 32.Ware, J. E., Kosinski, M., & Keller, S. D. (1995). SF-12: How to score the SF-12 physical and mental health summary scales. Boston, MA: The Health Institute, New England Medical Center.Google Scholar
- 33.Gandek, B., Ware, J. E., Aaronson, N. K., Apolone, G., Bjorner, J. B., Brazier, J. E., et al. (1998). Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: Results from the IQOLA project international quality of life assessment. Journal of Clinical Epidemiology, 51(11), 1171–1178.PubMedCrossRefGoogle Scholar
- 34.World Health Organization. (1993). Indicators and strategies for iron deficiency and anemia programmes (pp. 6–10). Report of the WHO/UNICEF/UNU Consultation. Geneva, Switzerland.Google Scholar
- 35.Woolf, N. (2007). Best practices: a little structure in your codes. Atlas.ti Newsletter. Available at: http://www.atlasti.com/downloads/ATLASti_Newsletter_2007_01.pdf.
- 36.Hays, R. D., & Revicki, D. A. (2005). Reliability and validity, including responsiveness. In P. Fayers & R. D. Hays (Eds.), Assessing quality of life in clinical trials. New York: Oxford University Press.Google Scholar
- 37.McColl, E. (2005). Developing questionnaires. In P. Fayers & R. Hays (Eds.), Assessing quality of life in clinical trials (pp. 9–23). New York: Oxford University Press.Google Scholar
- 38.Willis, G., Reeve, B., & Barofsky, I. (2004). The use of cognitive interviewing techniques in quality-of-life and patient-reported outcomes assessment. In J. Lipscomb, C. Gotay, & C. Synder (Eds.), Outcomes assessment in cancer: measures, methods and applications. Cambridge, UK: Cambridge University Press.Google Scholar
- 40.Harper, P. & Littlewood, T. (2005). Anaemia of cancer: impact on patient fatigue and long-term outcome. Oncology, 69(Suppl 2), 2–7.Google Scholar
- 43.Vogelzang, N. J., Breitbart, W., Cella, D., Curt, G. A., Groopman, J. E., Horning, S. J., et al. (1997). Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The fatigue coalition. Seminars in Hematology, 34(3 Suppl 2), 4–12.Google Scholar
- 44.Hedenus, M., Adriansson, M., San Miguel, J., Kramer, M. H., Schipperus, M. R., Juvonen, E., et al. (2003). Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. British Journal Haematology, 122(3), 394–403.CrossRefGoogle Scholar
- 45.Vansteenkiste, J., Pirker, R., Massuti, B., Barata, F., Font, A., Fiegl, M., et al. (2002). Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. Journal of the National Cancer Institute, 94(16), 1211–1220.PubMedCrossRefGoogle Scholar
- 46.Pirker, R., Ramlau, R. A., Schuette, W., Zatloukal, P., Ferreira, I., Lillie, T., et al. (2008). Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. Journal of Clinical Oncology, 26(14), 2342–2349.PubMedCrossRefGoogle Scholar
- 47.Cella, D., Lai, J. S., & Stone, A. (2010). Self-reported fatigue: One dimension or more? Lessons from the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire. Support Care Cancer.Google Scholar
- 48.Lai, J.-S., & Chen, W.-H. (2006). Fatigue archival analysis report prepared for: The PROMIS SCC analysis team. Available at: http://www.nihpromis.org/Data%20Analysis/FatigueArchivalAnalysisReport.doc.
- 49.Ryan, J. L., Carroll, J. K., Ryan, E. P., Mustian, K. M., Fiscella, K. & Morrow, G. R. (2007). Mechanisms of cancer-related fatigue. Oncologist, 12(Suppl 1), 22–34.Google Scholar